An Exploratory Study to Investigate the Effects of the NK1 Antagonist GW679769, 120 mg Once Daily for 4 Days, on Gastric Accommodation, Gastric Emptying and Gastric Distension-induced Perception and Discomfort in Adult Male and Female Patients With Functional Dyspepsia, in a Single Center, Placebo-controlled, Double-blind, Randomised, Two-period Crossover Study
Phase of Trial: Phase II
Latest Information Update: 10 Feb 2017
At a glance
- Drugs Casopitant (Primary)
- Indications Non-ulcer dyspepsia
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 27 May 2010 Actual end date (Aug 2006) added as reported by ClinicalTrials.gov.
- 03 Nov 2006 New trial record.